Sugi Predict

Sugi Predict / Targets / NMBR

NMBR

Neuromedin-B receptor · P28336 · NMBR on Sugi Atlas →

7,780 patent compounds predicted against NMBR, 5,032 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL397897 SCHEMBL397897 1.00 18/20
SCHEMBL397898 SCHEMBL397898 1.00 18/20
SCHEMBL881095 SCHEMBL881095 0.52 18/20
SCHEMBL6019142 SCHEMBL6019142 0.65 15/20
SCHEMBL6020210 SCHEMBL6020210 0.66 14/20
SCHEMBL6019326 SCHEMBL6019326 0.65 14/20
SCHEMBL6020628 SCHEMBL6020628 0.63 14/20
SCHEMBL6020423 SCHEMBL6020423 0.62 14/20
SCHEMBL6020259 SCHEMBL6020259 0.58 14/20
SCHEMBL6020248 SCHEMBL6020248 0.55 13/20
SCHEMBL6020364 SCHEMBL6020364 0.77 12/20
SCHEMBL6020039 SCHEMBL6020039 0.66 12/20
SCHEMBL6019706 SCHEMBL6019706 0.63 12/20
SCHEMBL6013894 SCHEMBL6013894 0.61 12/20
SCHEMBL5881088 SCHEMBL5881088 0.44 12/20
SCHEMBL2417039 SCHEMBL2417039 0.90 11/20
SCHEMBL2379686 SCHEMBL2379686 0.87 11/20
SCHEMBL6020516 SCHEMBL6020516 0.64 11/20
SCHEMBL6019145 SCHEMBL6019145 0.58 11/20
SCHEMBL4888176 SCHEMBL4888176 0.56 11/20

Clinical trials — most relevant to NMBR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Deep BLock on Intraoperative Surgical Conditions PHASE4COMPLETED
Interaction Between Magnesium and Neostigmine or Sugammadex for the Reversal of a Rocuronium-induced Neuromuscular Block PHASE4COMPLETED
CURES: The Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity PHASE4COMPLETED
Street Fitness in Surgical Patients Undergoing General Anesthesia After Reversal of Neuromuscular Blockade PHASE4UNKNOWN
Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC PHASE4COMPLETED
Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls PHASE4COMPLETED
OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER PHASE3UNKNOWN
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) PHASE2ACTIVE_NOT_RECRUITING
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System PHASE2WITHDRAWN
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease PHASE2COMPLETED
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma PHASE1/PHASE2NOT_YET_RECRUITING
Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium EARLY_PHASE1UNKNOWN
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients nanCOMPLETED
Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients? nanCOMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment nanNOT_YET_RECRUITING
Residual Neuromuscular Block in the Post-Anesthetic Unit and Postoperative Complications nanRECRUITING
Selective Activation of the Adrenomedullin Receptors in Migraine nanNOT_YET_RECRUITING
Association of Urine BDNF and NGF With Lower Urinary System Parameters nanRECRUITING
Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments nanRECRUITING
Cholinergic Nicotinic Receptors and Cognition in PD nanCOMPLETED
Repertoire and Properties of Anti-drug Antibodies Involved in Immediate Hypersensitivity in the Operating Room nanRECRUITING
L-arginine add-on Therapy in Patients With Schizophrenia nanCOMPLETED
Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome nanCOMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma nanCOMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
Comparison of Adductor Pollicis and Abductor Digiti Minimi Muscles (Thumb Vs. Fifth Digit) As Sites for Neuromuscular Monitoring with Electromyography nanRECRUITING
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia nanUNKNOWN
BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies nanCOMPLETED
Neuromarker S-100B as Diagnostic Tool nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NMBR binder may also engage these)

ProteinNameSimilarity
P24053 — 1.000 P24053 →
O54799 — 1.000 O54799 →
B2ZI34 — 1.000 B2ZI34 →
GRPR Gastrin-releasing peptide receptor 0.990 landscape →
P52500 — 0.985 P52500 →
P21729 — 0.981 P21729 →
P42866 — 0.962 P42866 →
Q5IS39 — 0.961 Q5IS39 →
P56479 — 0.960 P56479 →
Q95M54 — 0.959 Q95M54 →
P33534 — 0.959 P33534 →
P33535 — 0.959 P33535 →
P34975 — 0.957 P34975 →
Q62805 — 0.957 Q62805 →
P79350 — 0.955 P79350 →
Q61614 — 0.955 Q61614 →
Q5IS84 — 0.955 Q5IS84 →
Q95247 — 0.955 Q95247 →
OPRM1 Mu-type opioid receptor 0.955 landscape →
EDNRB Endothelin receptor type B 0.954 landscape →
Q5KSU9 — 0.953 Q5KSU9 →
Q9MYW9 — 0.953 Q9MYW9 →
OPRK1 Kappa-type opioid receptor 0.953 landscape →
P21450 — 0.953 P21450 →
P26684 — 0.952 P26684 →
O62709 — 0.952 O62709 →
Q95L55 — 0.951 Q95L55 →
P41144 — 0.951 P41144 →
EDNRA Endothelin-1 receptor 0.951 landscape →
P21451 — 0.950 P21451 →